Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry

INTRODUCTION: In clinical trials, treatment with the interleukin-23 inhibitor guselkumab was associated with significantly improved disease severity and patient-reported outcome measures (PROMs) among patients with moderate-to-severe plaque psoriasis. However, limited information is available regard...

Descripción completa

Detalles Bibliográficos
Autores principales: Armstrong, April W., Fitzgerald, Timothy, McLean, Robert R., Teeple, Amanda, Uy, Jonathan P., Olurinde, Mobolaji, Rowland, Katelyn, Guo, Lin, Shan, Ying, Callis Duffin, Kristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884726/
https://www.ncbi.nlm.nih.gov/pubmed/36484917
http://dx.doi.org/10.1007/s13555-022-00865-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884726/
https://www.ncbi.nlm.nih.gov/pubmed/36484917
http://dx.doi.org/10.1007/s13555-022-00865-0

Ejemplares similares